Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Unknown 2Terminated 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 4Urologic Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Hemorrhage 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Advanced Ovarian Cancer 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 24Carboplatin 21Paclitaxel 20olaparib 19Magnetic Resonance Spectroscopy 14Bevacizumab 14Cyclophosphamide 12Specimen Handling 11Nivolumab 11Gemcitabine 11Taxes 10niraparib 8Cisplatin 8Biopsy 8liposomal doxorubicin 7fludarabine 7Surveys and Questionnaires 6Immunoglobulin G 6Doxorubicin 6Disulfides 6durvalumab 5palbociclib 4oregovomab 4X-Rays 4Ipilimumab 4mirvetuximab soravtansine 3ipatasertib 3defactinib 3cediranib 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Ovarian Neoplasms × Saline Solution × Clear all
NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡